Fahriye Tugba Kos
Overview
Explore the profile of Fahriye Tugba Kos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
32
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seven I, Bayram D, Arslan H, Kos F, Gumuslu K, Akturk Esen S, et al.
Sci Rep
. 2025 Feb;
15(1):6226.
PMID: 39979406
Despite the extensive research on hepatocellular carcinoma (HCC) exploring various treatment strategies, the survival outcomes have remained unsatisfactory. The aim of this research was to evaluate the ability of machine...
2.
Perkin P, Sekmek S, Bayram D, Kos F
J Chemother
. 2025 Feb;
:1-5.
PMID: 39972542
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs). Pembrolizumab, an anti-PD-1 antibody, is widely used in non-small cell lung cancer (NSCLC), yet...
3.
Kos F, Cecen Kaynak S, Akturk Esen S, Arslan H, Uncu D
Cureus
. 2025 Jan;
16(12):e75713.
PMID: 39811215
Introduction: In recent years, machine learning (ML) methods have gained significant popularity among medical researchers interested in cancer. We aimed to test different (ML) models to predict both overall survival...
4.
Seven I, Kos F, Tatli Dogan H, Kislal M, Sekmek S, Karahan I, et al.
Anticancer Drugs
. 2025 Jan;
36(2):151-153.
PMID: 39749551
Epidermal growth factor receptor (EGFR) mutations like the common L858R and exon 19 deletions are well studied, but rarer mutations like exon 19 insertions have received less attention. This case...
5.
Cakmak M, Bal O, Kiraci M, Topaloglu O, Kos F, Algin E
Anticancer Drugs
. 2024 Dec;
36(2):140-142.
PMID: 39625742
Hypoglycemia is a medical emergency with a multitude of potential causes. Paraneoplastic hypoglycemia represents a rare cause of this condition. Hepatocellular carcinoma (HCC) can result in paraneoplastic hypoglycemia through extensive...
6.
Sekmek S, Ozsan Celebi S, Bayram D, Erol C, Kos F, Sendur M, et al.
Sci Rep
. 2024 Nov;
14(1):29785.
PMID: 39616250
We aimed to compare FOLFIRI and bevacizumab with FOLFIRI and aflibercept in terms of overall survival (OS), progression-free survival (PFS) and safety in patients with RAS-mutant metastatic colon cancer who...
7.
Ulas A, Temel B, Kos F
Medicina (Kaunas)
. 2024 Nov;
60(11).
PMID: 39596977
: In this study, we evaluated the impact of seven immune indexes on treatment response and survival outcomes in advanced non-small-cell lung cancer (NSCLC) patients receiving second-line and subsequent nivolumab...
8.
Bayram D, Sekmek S, Kayaalp M, Bardakci M, Hafizoglu E, Ucar G, et al.
Indian J Thorac Cardiovasc Surg
. 2024 Oct;
40(6):660-668.
PMID: 39416339
Introduction: Thymic epithelial tumors represent the most common cause of anterior mediastinal masses in adults. Among these tumors, thymomas constitute the majority, whereas thymic carcinomas are less prevalent and associated...
9.
Seven I, Karahan I, Kos F, Bayram D, Sekmek S, Akturk Esen S
Clin Transl Oncol
. 2024 Sep;
PMID: 39271621
Background: Biliary tract cancers are serious diseases and new biomarkers may be useful for the optimal management and prediction of these cases. This study aimed to evaluate the prognostic significance...
10.
Kiraci M, Akturk Esen S, Turkay D, Kos F
J Oncol Pharm Pract
. 2024 Aug;
30(8):1455-1459.
PMID: 39095043
Introduction: Pembrolizumab is a humanized monoclonal antibody IgG4 programmed cell death protein 1 antagonist, and its use in oncology has been increasing in recent years, providing durable and favorable responses...